Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The study shows that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic HBV infection. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 70.8 percent of patients in the Viread arm (n=250) had a complete response compared to 48.8 percent in the Hepsera arm (n=125; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections, creatinine phosphokinase and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the incidence of grade 3 or 4 laboratory abnormalities was comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

"Chronic hepatitis B remains a serious disease that impacts more than one million people in the United States and an estimated 400 million people worldwide," said Franck Rousseau, MD, Vice President, Clinical Research, Gilead Sciences.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/23/2015)... For the pharmaceutical industry, marketplace success is tied to how ... of the managed markets function - which is pharma,s interface ... formularies and provider networks play an increasingly large role in ... managed markets leaders must continually identify the optimal resource levels ...
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 21, 2007-Novo Nordisk today announced clinical,results from the ... -,the once-daily human GLP-1 analogue. The 26-week study ... in Diabetes) programme,and included 581 patients with type ... widely used oral antidiabetic drugs:,metformin and a sulfonylurea ...
... N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Nymox,Pharmaceutical Corporation ... the Company's recently completed studies of,NX-1207 for ... at,a series of upcoming U.S. urology meetings, ... Urological Association Meeting in,Colorado Springs. These independent ...
Cached Medicine Technology:Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 2Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 3Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study 4Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... DAYTON, Ohio, Dec. 17 Good Samaritan Hospital is changing the ... launch of the Good Samaritan Hospital Women,s Center For Bladder & ... common medical problems - lack of bladder control (urinary incontinence) and ... out of four women report some degree of urinary leakage and ...
... recent Thomson Reuters study show that Chinese research output has ... 112,000 in 2008. Faculty of 1000, which selects ... more than 530 papers from Chinese universities and institutes since ... this increased by over fourfold in 2008 and is set ...
... ... uniquely designed, extremely resilient, ‘two-in-one’ foam roller. This patented foam roller has one side ... most versatile foam rollers available. , ... Minneapolis, MN (PRWEB) December 17, 2009 -- The SMARTROLLER® from ...
... ... redesigned Web site: www.psanj.com . PSANJ is a leading cosmetic surgery center in the ... Jersey Monthly. , ... NJ (PRWEB) December 17, 2009 -- Plastic Surgery Arts of New Jersey (PSANJ) is pleased ...
... ... lead the firm’s Interim Leadership division as senior vice president. A seasoned executive with nearly ... Smith today. , ... (Vocus) December 17, 2009 -- B. E. Smith recently hired Deirdre Byrne to ...
... TROY, Mich., Dec. 17 CareTech Solutions ( www.CareTech.com ), ... for hospitals and health systems, was named Best in KLAS, ... Top 20 Best in KLAS Awards: Software & Professional Services ... vendors in key market segments including EMRs, cardiology systems, IT ...
Cached Medicine News:Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:China rapidly catching up in research impact 2Health News:OPTP Introduces the SMARTROLLER 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 2Health News:Plastic Surgery Arts of New Jersey (PSANJ) Launches New Web Site 3Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 2Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 3
... Safely And Easily Cut Foldable Silicone ... To Cut And Remove Even High ... One Instrument.,New Miniaturized Profile Allows Insertion ... Explantation Of A Silicone Lens.,Available For ...
... Unit, Shaped Like A Fan, And Enable The ... Incision. The Gauges Start At A Width Of ... With 100-Micron Increments. The Gauges Are Easy ... The Preoperative And Postoperative Incision Result. Reusable, Autoclaveable, ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
Medicine Products: